USPTO serial 99357587
UROBIOTX
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- WOOD, DANIEL PAUL
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with UROBIOTX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Wilmington, DE, US
Wilmington, DE, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew S. Langsam
Andrew S. Langsam Law Office of Andrew S. Langsam, PLLC28 Limestone RoadArmonk, NY 10504United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Cleaning agents and preparations; Cleaning preparations with a solvent base; Cleaning solvents, other than for use in manufacturing processes; Cleaning preparations; Preparations for cleaning surfaces; Cleaning and washing preparations and substances | ACTIVE | — |
| 005 | Scientific research for medical purposes; Scientific research services for medical purposes; Biological research services; Medical research laboratory services; Scientific research and development; Scientific research in the field of urinary system pathologies; Research in the field of chemistry; Bacteriological research and analysis; Biological research and analysis in the field of urinary system pathologies; Research laboratories, namely, medical research laboratories in the field of urinary system pathologies; Scientific research and analysis related to urinary system pathologies; Biological research; Clinical research in the field of urinary system pathologies; Medical research; Medical research laboratories; Research to develop new products for others; Biological research and clinical research in the field of urinary system pathologies and medical research; Medical research and development of medicinal preparations to understand, treat, and prevent pathologies of the urinary system; Scientific and medical research and development of medicinal preparations, namely, to treat and prevent pathologies of the urinary system; Biological, medical, and clinical research in the field of urinary system pathologies; Research and development of medicines; Biotechnological research; Research and development in the field of biomedicine; Scientific research; Scientific research in the field of chemistry; Chemistry research; Research in the fields of chemistry and biology; Research in the field of biochemistry; Bacteriological research and testing; Research relating to bacteriology; Scientific research relating to bacteriology; Research in the field of bacteriology; Research and development in the field of biotechnology; Research in the field of biotechnology; Scientific research in the field of biotechnology; Research relating to biotechnology; Biotechnology research; Medical research services; Scientific research and development services; Medical research; Medical research and development in the field of urinary system pathologies; Biomedical research; Biomedical research services | ACTIVE | — |
| 042 | scientific research for medical purposes; scientific research services for medical purposes; biological research services; medical research laboratory services; scientific research and development; scientific research in the field of urinary system pathologies; research in the field of chemistry; bacteriological research and analysis; biological research and analysis in the field of urinary system pathologies; research laboratories, namely medical research laboratories in the field of urinary system pathologies; scientific research and analysis related to urinary system pathologies; biological research; clinical research in the field of urinary system pathologies; medical research; medical research laboratories; research to develop new products for others; biological research, clinical research in the field of urinary system pathologies and medical research; medical research and development of medicinal preparations to understand, treat and prevent pathologies of the urinary system; scientific and medical research and development of medicinal preparations, namely to treat and prevent pathologies of the urinary system; biological, medical research and clinical research in the field of urinary system pathologies; research and development of medicines; biotechnological research; research and development in the field of biomedicine; scientific research; scientific research in the field of chemistry; chemistry research; research in the fields of chemistry and biology; research in the field of biochemistry; bacteriological research and testing; research relating to bacteriology; scientific research relating to bacteriology; research in the field of bacteriology; research and development in the field of biotechnology; research in the field of biotechnology; scientific research in the field of biotechnology; research relating to biotechnology; biotechnology research; medical research services; scientific research and development services; and medical research and; and medical research and development in the field of urinary system pathologies; biomedical research; biomedical research services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 24, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 24, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 24, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 24, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 14, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 17, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 17, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 11, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 23, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 23, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 23, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 23, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 23, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 16, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 16, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 15, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 26, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 26, 2025 | NWAP | NEW APPLICATION ENTERED | — |